Low‑Metabolic‑Risk Antipsychotic Guideline Summary (2025 INTEGRATE)
Preferred First‑Line Agents with Favorable Metabolic Profiles
- The INTEGRATE international schizophrenia guidelines (2025) recommend aripiprazole and cariprazine as the preferred options when switching antipsychotics to address metabolic concerns or negative symptoms, citing superior tolerability across weight, glucose, and lipid parameters. [1][2]
- Aripiprazole, ziprasidone, and lurasidone are highlighted as having the most benign metabolic profiles among all agents, showing minimal weight gain, glucose dysregulation, and lipid abnormalities in a large network meta‑analysis (18 antipsychotics; ≈ 26 000 patients). Evidence graded as high (multiple randomized trials). [1][2]
Agents to Avoid or Use with Caution
- Olanzapine and clozapine are identified as having poor cardiometabolic profiles; initiation should be accompanied by adjunctive metformin to mitigate weight gain and dyslipidaemia. Strength of recommendation: strong (guideline consensus). [1][2]3
- Quetiapine carries a high anticholinergic burden and an intermediate metabolic risk, warranting careful consideration when metabolic safety is a priority. 2
Clinical Decision Criteria for Prioritizing Low‑Metabolic Agents
- Switch to a metabolically favorable antipsychotic when positive symptoms are well controlled and a dose reduction within the therapeutic range is feasible. 2
- Consider switching when cognitive symptoms emerge, as agents such as olanzapine, clozapine, and quetiapine have the highest anticholinergic activity. 3
Baseline and Ongoing Monitoring Requirements
| Parameter | Timing | Evidence Source |
|---|---|---|
| BMI, waist circumference, blood pressure | Baseline; weekly for 6 weeks, then at 3 months and annually | [3] |
| HbA1c, fasting glucose, lipid panel | Baseline; fasting glucose re‑checked at 4 weeks; full panel repeated at 3 months and annually | [3] |
| Prolactin, liver function, renal function, CBC, ECG | Baseline; repeat annually or as clinically indicated | [3] |
- Fasting glucose must be rechecked 4 weeks after initiation of any antipsychotic. [2][3]
- BMI, waist circumference, and blood pressure require weekly monitoring for the first 6 weeks, followed by reassessment at 3 months and then yearly. [2][3]
Adjunctive Strategies When High‑Risk Agents Are Required
- If olanzapine or clozapine must be used (e.g., treatment‑resistant schizophrenia), initiate adjunctive metformin (starting 500 mg daily, titrating to 1 g twice daily over 2 weeks). 3
- Use a modified‑release metformin formulation to reduce gastrointestinal side effects. 3
- Check renal function before starting metformin and avoid in patients with renal failure. 3
- Annual monitoring while on metformin should include liver function, HbA1c, renal function, and vitamin B12 levels. 3
Additional Considerations
- Low‑dose amisulpride (≈ 50 mg twice daily) may be considered for predominant negative symptoms when positive symptoms are stable; it has an intermediate metabolic impact. 2
- The guideline emphasizes that aripiprazole, cariprazine, ziprasidone, and lurasidone constitute the evidence‑based first‑line choices when metabolic safety is paramount, reflecting the most recent INTEGRATE algorithmic approach. [1][2]